1 / 12

Aarkstore - Type 2 Diabetes - Pipeline Review, H2 2014

Type 2 Diabetes - Pipeline Review, H2 2014 report reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects. Browse full report @ http://goo.gl/IELRmH

Télécharger la présentation

Aarkstore - Type 2 Diabetes - Pipeline Review, H2 2014

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Pharmaceutical and Healthcare Market Research Report Type 2 Diabetes - Pipeline Review, H2 2014 For More Information Visit : www.aarkstore.com

  2. Summary Type 2 Diabetes - Pipeline Review, H2 2014, provides an overview of the Type 2 Diabetess therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Type 2 Diabetes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. For More Information Visit : www.aarkstore.com

  3. Scope - The report provides a snapshot of the global therapeutic landscape of Type 2 Diabetes- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Type 2 Diabetes and enlists all their major and minor projects- The report summarizes all the dormant and discontinued pipeline projects - A review of the Type 2 Diabetes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages- A detailed assessment of monotherapy and combination therapy pipeline projects- Coverage of the Type 2 Diabetes pipeline on the basis of target, MoA, route of administration and molecule type- Latest news and deals relating related to pipeline products For More Information Visit : www.aarkstore.com

  4. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Develop strategic initiatives by understanding the focus areas of leading companies- Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline- Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline For More Information Visit : www.aarkstore.com

  5. Table of Content Introduction 9Type 2 Diabetes Overview 10Therapeutics Development 11Type 2 Diabetes - Therapeutics under Development by Companies 13Type 2 Diabetes - Therapeutics under Investigation by Universities/Institutes 31Type 2 Diabetes - Pipeline Products Glance 33Type 2 Diabetes - Products under Development by Companies 37Type 2 Diabetes - Products under Investigation by Universities/Institutes 57Type 2 Diabetes - Companies Involved in Therapeutics Development 60Type 2 Diabetes - Therapeutics Assessment 267Drug Profiles 293Type 2 Diabetes - Recent Pipeline Updates 986Type 2 Diabetes - Dormant Projects 1095Type 2 Diabetes - Discontinued Products 1106Type 2 Diabetes - Product Development Milestones 1111Appendix 1119 For More Information Visit : www.aarkstore.com

  6. List of Tables Number of Products under Development for Type 2 Diabetes, H2 2014 69Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H2 2014 70Number of Products under Development by Companies, H2 2014 72Number of Products under Development by Companies, H2 2014 (Contd..1) 73Number of Products under Development by Companies, H2 2014 (Contd..2) 74Number of Products under Development by Companies, H2 2014 (Contd..3) 75Number of Products under Development by Companies, H2 2014 (Contd..4) 76Number of Products under Development by Companies, H2 2014 (Contd..5) 77Number of Products under Development by Companies, H2 2014 (Contd..6) 78Number of Products under Development by Companies, H2 2014 (Contd..7) 79Number of Products under Development by Companies, H2 2014 (Contd..8) 80Number of Products under Development by Companies, H2 2014 (Contd..9) 81Number of Products under Development by Companies, H2 2014 (Contd..10) 82Number of Products under Development by Companies, H2 2014 (Contd..11) 83Number of Products under Development by Companies, H2 2014 (Contd..12) 84 For More Information Visit : www.aarkstore.com

  7. List of Figures Number of Products under Development for Type 2 Diabetes, H2 2014 69Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H2 2014 70Number of Products under Development by Companies, H2 2014 71Number of Products under Investigation by Universities/Institutes, H2 2014 89Comparative Analysis by Late Stage Development, H2 2014 91Comparative Analysis by Clinical Stage Development, H2 2014 92Comparative Analysis by Early Stage Products, H2 2014 93Assessment by Monotherapy Products, H2 2014 325Assessment by Combination Products, H2 2014 326Number of Products by Top 10 Targets, H2 2014 327Number of Products by Stage and Top 10 Targets, H2 2014 327Number of Products by Top 10 Mechanism of Actions, H2 2014 337Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 337Number of Products by Top 10 Routes of Administration, H2 2014 347 For More Information Visit : www.aarkstore.com

  8. List of Figures Number of Products under Development for Type 2 Diabetes, H2 2014 69Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H2 2014 70Number of Products under Development by Companies, H2 2014 71Number of Products under Investigation by Universities/Institutes, H2 2014 89Comparative Analysis by Late Stage Development, H2 2014 91Comparative Analysis by Clinical Stage Development, H2 2014 92Comparative Analysis by Early Stage Products, H2 2014 93Assessment by Monotherapy Products, H2 2014 325Assessment by Combination Products, H2 2014 326Number of Products by Top 10 Targets, H2 2014 327Number of Products by Stage and Top 10 Targets, H2 2014 327Number of Products by Top 10 Mechanism of Actions, H2 2014 337Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 337Number of Products by Top 10 Routes of Administration, H2 2014 347 For More Information Visit : www.aarkstore.com

  9. Browse Full Report Or Sample Request @ http://www.aarkstore.com/pharmaceuticals-healthcare/60599/type-2-diabetes-pipeline-review-h2-2014 For More Information Visit : www.aarkstore.com

  10. Related Reports Sinusitis-Pipeline Insights, 2015 Oligodendroglioma-Pipeline Insights, 2015 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)-Pipeline Insights, 2015 Fatty Liver Disease-Pipeline Insights, 2015 Skin And Skin Structure Infections by S.Pneumoniae-Pipeline Insights, 2015 Opioid-Induced Constipation (OIC)-Pipeline Insights, 2015 Female Infertility-Pipeline Insights, 2015 Optic Neuritis-Pipeline Insights, 2015 For More Information Visit : www.aarkstore.com

  11. Follow Us https://www.facebook.com/aarkstoredotcom https://twitter.com/aarkstore https://plus.google.com/+Aarkstoredotcom/posts https://www.linkedin.com/company/aarkstore-enterprise For More Information Visit : www.aarkstore.com

  12. Contact Us Office Address Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Mail us at contact@aarkstore.com 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 For More Information Visit : www.aarkstore.com

More Related